• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Meier Thomas

    2/16/24 4:05:11 PM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BWV alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Meier Thomas

    (Last) (First) (Middle)
    C/O ONCONETIX, INC.
    201 E. FIFTH STREET, SUITE 1900

    (Street)
    CINCINNATI OH 45202

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    02/06/2024
    3. Issuer Name and Ticker or Trading Symbol
    Onconetix, Inc. [ ONCO ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Thomas Meier 02/16/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BWV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BWV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BWV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

      CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (NASDAQ:BWV) ("Onconetix" or the "Company") today issued the following shareholder letter from the Company's Chief Executive Officer, Dr. Neil Campbell. To Our Valued Shareholders, As 2023 draws to a close, I am eager to share with you the significant strides Onconetix, Inc. (formerly Blue Water Biotech, Inc.) has made in our journey towards becoming a leader in oncology. This past quarter has been transformative, marked by strategic shifts and notable achievements, all aimed at enhancing the value we bring to you as our shareholders. To reflect our recent achievements and renewed oncology focus, we have rebranded as Onconet

      12/19/23 7:00:00 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

      CINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV) ("BWB" or the "Company") today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology company (the "Transaction"), and introduced a new name for the combined Company: Onconetix, Inc. The Transaction reflects a transformation of the business to one focused on the research, development and commercialization of proprietary science and technologies for therapeutics, diagnostics and services for the treatment of cancer. The acquisition of Proteomedix for all stock consideration provides its shareholders with an initial 19.9% ownership stake of Onconetix. With the tran

      12/18/23 7:00:00 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company

      CINCINNATI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV) ("BWB" or the "Company"), today announced the execution of a non-binding term sheet regarding the acquisition of a private commercial stage oncology biotechnology company (the "Proposed Transaction"). This latest announcement is part of the Company's new business strategy focusing on oncology. The Company plans to commercialize therapeutics, diagnostics and clinician services, which will serve as the foundation for the Company's future operations. The Proposed Transaction furthers a shift in business strategy driven by BWB's decision to align with both the market value drivers provided by its new oncolog

      11/2/23 7:00:00 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BWV
    SEC Filings

    See more
    • SEC Form S-1 filed by Blue Water Biotech Inc.

      S-1 - Onconetix, Inc. (0001782107) (Filer)

      2/14/24 5:06:02 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Blue Water Biotech Inc.

      PRE 14A - Onconetix, Inc. (0001782107) (Filer)

      2/14/24 5:04:25 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blue Water Biotech Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Onconetix, Inc. (0001782107) (Filer)

      2/13/24 8:24:20 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BWV
    Leadership Updates

    Live Leadership Updates

    See more
    • Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO

      CINCINNATI, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV), which is focused on developing and commercializing transformational therapies to address significant global health challenges, today announced the appointments of Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO, effective immediately. Dr. Campbell has also joined the Company's board of directors. Dr. Campbell has more than 35 years of experience with public and private companies focused on biopharmaceuticals, health technologies, nanotechnologies, artificial intelligence and super-computing. He has held leadership positions with IGEN International, now Roche; Celera Genomics; and Abbott

      10/10/23 9:00:00 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer

      CINCINNATI, April 26, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the "Company"), a biotechnology company spanning multiple sectors, today announced the appointment of Jay Newmark, M.D., MBA as the Company's Chief Medical Officer. Dr. Newmark is a board-certified urologist with over 30 years of experience managing Men's Health issues, including benign prostatic hyperplasia ("BPH"). Blue Water currently owns ENTADFI®, an FDA-approved treatment for BPH that counteracts negative sexual side effects seen in men on alternative BPH therapies. Dr. Newmark's appointment will support Blue Water's upcoming launch of ENTADFI® and he will work closely with Blue Water management

      4/26/23 3:44:02 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development

      CINCINNATI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), today announced the appointment of Frank Jaeger, seasoned commercial operations and business development executive, as Senior Vice President of Marketing and Business Development. Mr. Jaeger brings over 25 years of biopharmaceutical experience to the BWV team, from start-up to large global pharma with significant pre-launch, launch, and in-market commercialization experience. His background in R&D, Medical Affairs, Business Development, and throughout Commercial Operations provides a broad world view and an understanding of varying perspectives. Mr. Jaeger has a wide r

      2/6/23 10:15:00 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BWV
    Financials

    Live finance-specific insights

    See more
    • Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

      CINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV) ("BWB" or the "Company") today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology company (the "Transaction"), and introduced a new name for the combined Company: Onconetix, Inc. The Transaction reflects a transformation of the business to one focused on the research, development and commercialization of proprietary science and technologies for therapeutics, diagnostics and services for the treatment of cancer. The acquisition of Proteomedix for all stock consideration provides its shareholders with an initial 19.9% ownership stake of Onconetix. With the tran

      12/18/23 7:00:00 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights

      CINCINNATI, May 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the "Company"), a biotechnology company spanning multiple sectors, today announced its financial results for the quarter ended March 31, 2023 and provided an update on recent business developments and Company progress. Blue Water Biotech is a biological and pharmaceutical technology company developing multiple preclinical vaccine candidates across various infectious diseases and owns the FDA-approved benign hyperplasia ("BPH") asset, ENTADFI®. "Blue Water's recent growth is highlighted by our acquisition of ENTADFI®, as well as our subsequent rebranding initiative and name change to reflect our transiti

      5/12/23 6:32:51 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset

      Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate Name Change to Underscore Broader Focus Company to Host a Conference call Today, April 20th, at 8:30am EDT to Discuss Asset Purchase and Company Transformation CINCINNATI, April 20, 2023 (GLOBE NEWSWIRE) --  Blue Water Vaccines Inc. ("BWV" or "Blue Water" or the "Company"), today announced the signing of an Asset Purchase Agreement (the "Agreement") with Veru Inc. ("Veru") for the purchase of ENTADFI®, an FDA-approved treatment for benign prostatic hyperplasia ("BPH") that counteracts negative sexual side effects seen in men on alternative BPH therapies. Unde

      4/20/23 7:30:00 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BWV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Blue Water Biotech Inc. (Amendment)

      SC 13G/A - Onconetix, Inc. (0001782107) (Subject)

      1/26/24 6:01:11 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Blue Water Biotech Inc. (Amendment)

      SC 13G/A - Onconetix, Inc. (0001782107) (Subject)

      1/2/24 1:13:20 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Blue Water Biotech Inc.

      SC 13G - Onconetix, Inc. (0001782107) (Subject)

      12/27/23 6:34:55 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BWV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Singh Ajit

      3 - Onconetix, Inc. (0001782107) (Issuer)

      2/16/24 4:05:21 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Meier Thomas

      3 - Onconetix, Inc. (0001782107) (Issuer)

      2/16/24 4:05:11 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Schiess Ralph claimed ownership of 269,749 shares (SEC Form 3)

      3 - Onconetix, Inc. (0001782107) (Issuer)

      1/3/24 4:05:49 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care